Beclamide

Beclamide
Clinical data
Routes of; administration	By mouth
ATC code	N03AX30 (WHO) ;
Identifiers
	IUPAC name N-Benzyl-3-chloropropanamide;
CAS Number	501-68-8 ;
PubChem CID	10391;
ChemSpider	9962 ;
UNII	F5N0ALI65V;
KEGG	D07300 ;
ChEMBL	ChEMBL64195 ;
CompTox Dashboard (EPA)	DTXSID5057755 ;
ECHA InfoCard	100.007.207
Chemical and physical data
Formula	C10H12ClNO
Molar mass	197.66 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	94 °C (201 °F)
	SMILES ClCCC(=O)NCc1ccccc1;
	InChI InChI=1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13) ; Key:JPYQFYIEOUVJDU-UHFFFAOYSA-N ;
	(verify)

Beclamide (marketed as Chloracon, Hibicon, Posedrine, Nydrane, Seclar, and other names) is a drug that possesses anticonvulsant activity.^[1] It is no longer used.

Uses

It has been used as a sedative and as an anticonvulsant.

It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures.

Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia.^[2]

Side effects

Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.

Administration and pharmacology

Administration is oral, though it has an unpleasant taste. It is quickly absorbed and elimination is renal and complete within 48 hours. Beclamide is possibly metabolized to 3-chloropropanoic acid in vivo, which binds to the GHB receptor.

References

↑ Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of Pharmacy and Pharmacology. 47 (10): 876–8. doi:10.1111/j.2042-7158.1995.tb05757.x. PMID 8583359.
↑ Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica. 81 (2): 162–7. doi:10.1111/j.1600-0447.1990.tb06472.x. PMID 2183543. S2CID 26772370.

The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid8583359-1] Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of Pharmacy and Pharmacology. 47 (10): 876–8. doi:10.1111/j.2042-7158.1995.tb05757.x. PMID 8583359.

[pmid2183543-2] Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica. 81 (2): 162–7. doi:10.1111/j.1600-0447.1990.tb06472.x. PMID 2183543. S2CID 26772370.

[1]

[2]